- Delcath Systems develops drug/device combos to treat liver cancers.
- The company’s stock is underappreciated due to past clinical failures and a de-listing despite promising clinical data.
- Delcath updated the trial design for its lead product to address past issues around patient recruitment and toxicity.
- With approval in Europe and a track record of treatment, Delcath's US trial is de-risked.
- The investment thesis for Delcath is a binary event centered around an upcoming clinical trial readout in the US for its lead product.
For further details see:
Delcath Systems: Cancer-Treatment Device Company With Upcoming Phase 3 Readout